Recalibrating Perceptions and Attitudes Toward Nebulizers versus Inhalers for Maintenance Therapy in COPD: Past as Prologue

Rajiv Dhand,Michael Hess,Abebaw Yohannes

DOI: https://doi.org/10.2147/copd.s491275

2024-11-29

International Journal of COPD

Abstract:Rajiv Dhand, 1 Michael W Hess, 2 Abebaw Mengistu Yohannes 3, 4 1 Division of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Tennessee Graduate School of Medicine, Knoxville, TN, USA; 2 COPD Foundation, Miami, FL, USA; 3 Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, USA; 4 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA Correspondence: Abebaw Mengistu Yohannes, 372 School of Health Professions, Department of Physical Therapy, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA, Tel +1 (205) 996 1579, Email Aerosol therapy administered via handheld inhaler or nebulizer device has long been standard for the treatment of chronic obstructive pulmonary disease (COPD), both for maintenance therapy and for management of acute exacerbations. Of the 2 options for drug delivery, inhaler devices are the most widely used for ambulatory patients with COPD as they are small, portable, and convenient and offer an array of medication options. They are, however, prone to suboptimal inhalation technique and use errors, which decrease the amount of medication delivered, compromise efficacy, and adversely affect clinical outcomes. Nebulizers are less often employed for aerosol delivery than inhalers, particularly in the home environment. Considered bulky and expensive, nebulizers have historically had limited medication options compared with inhalers. Nonetheless, nebulizers may be preferred over inhalers in specific patient populations, such as in patients with poor lung function, lack of hand–breath coordination, or cognitive impairment. Furthermore, technological advances and development of new nebulizer-compatible medications are shifting the benefit equation for nebulizers versus inhalers in a way that merits reconsideration of the role of nebulizers in the maintenance treatment of COPD. Using the available literature, this state-of-the-art review critically evaluates the benefits and limitations of aerosol therapy delivery via inhaler or nebulizer for patients with COPD; describes the factors that may influence the benefit equation, including current advances in nebulizer technology and future developments; and provides insights on implementation of nebulizer therapy in clinical practice. Keywords: Aerosol therapy, bronchodilator, COPD, exacerbation, inhaler, maintenance Worldwide, there are an estimated 480 million people living with chronic obstructive pulmonary disease (COPD), and this number is anticipated to grow to approximately 600 million by 2050. 1 Although historically considered a disease predominantly caused by tobacco exposure, other factors (eg, air pollution, occupational exposures, poorly controlled asthma, infectious disease, cooking fuel smoke, low socioeconomic status, impaired childhood lung growth due to early-life exposures) are now considered to play a significant role in COPD development. 2 COPD has a tremendous impact on patients' lives, reducing quality of life, causing disability, decreasing social interaction, heightening anxiety and depressive symptoms, increasing risk of acute exacerbations and frequent hospitalizations, and contributing to morbidity and premature mortality. 3,4 Aerosol therapy—delivered via nebulizer, dry powder inhaler (DPI), pressurized metered-dose inhaler (pMDI), or soft mist inhaler (SMI)—is a mainstay of COPD treatment as well other respiratory conditions such as asthma and cystic fibrosis. 5 Aerosol therapies deliver medication directly to the lungs, providing rapid onset of effect and high local drug concentration, thereby increasing efficacy while reducing the risk for side effects associated with increased systemic exposure after oral or intravenous administration. 6,7 Handheld inhaler devices have long been used more frequently than nebulizers for aerosol therapy delivery. 8–11 Despite the importance and ubiquity of inhaler-based therapies, suboptimal treatment is common because of poor adherence and errors in device use, particularly in patients with COPD who have challenges related to advanced age, cognitive impairment, muscle weakness, and/or comorbidities. 12–14 Improper inhaler technique/device use errors are associated with increased exacerbation risk, 15–18 worse health status, 16,17 overuse of inhaled corticosteroids, 19 frequent episodes of emergency care utilization and hospitalizations, 20 and higher costs. 21 By contrast, optimizing inhaler technique reduces the rates of exacerbations and hospital admissions; 22 improves measures of disease -Abstract Truncated-

respiratory system